糖尿病治療の世界市場 (インスリン、OAD、GLP-1) ：産業分析・見通し
Global Diabetes Care Market (Insulin, OAD & GLP-1): Industry Analysis & Outlook (2019-2023)
|出版日||ページ情報||英文 120 Pages
|糖尿病治療の世界市場 (インスリン、OAD、GLP-1) ：産業分析・見通し Global Diabetes Care Market (Insulin, OAD & GLP-1): Industry Analysis & Outlook (2019-2023)|
|出版日: 2019年06月01日||ページ情報: 英文 120 Pages||
Diabetes, referred to diabetes mellitus, is a group of metabolic disorders which abnormally affect the level of sugar (glucose) in blood. Diabetes can either be due to pancreas not producing enough insulin or irresponsiveness of cells of the body to insulin. Insulin is a hormone which regulates the metabolism of carbohydrates, fat and protein by absorbing glucose (sugar) from the blood into fat, liver and skeletal muscles.
Diabetic population is growing considerably all over the world. AAMEO region is experiencing the highest prevalence of diabetes compared to other parts of world. Increasing population in AAMEO countries is the key reason supporting the diabetic population. Every geographical region is witnessing growth in their respective diabetes care market due to this increasing prevalence of diabetes.
Global diabetes care market is majorly dominated by insulin segment. Insulin segment is broadly divided into modern insulin and human insulin. Modern insulin is growing at a faster rate than human insulin market. In terms of mode of action, insulin market is dominated by long acting insulin.
Geographically, North America holds the highest share in global diabetes care market due to its advanced healthcare system along with increasing diabetic population. However, in global insulin market, Europe holds the highest share.
Global diabetes market is highly consolidated in nature with three key players including Novo Nordisk; Sanofi; and Eli Lilly. These three companies are holding major shares in every regional diabetes market. Among all these companies, Novo Nordisk is leading in every region.